In Q4 FY24, JB Pharma recorded a revenue of Rs 862 crores, marking a 13 per cent increase from Rs 762 crores in Q4 FY23
Read More
"The Indian pharmaceutical market for chronic diseases is experiencing significant growth. By leveraging our expertise in chronic therapies and dedication to innovation and brand development, JB Pharma is well-positioned to continue its upward trajectory in the Indian pharmaceutical market." - Dilip Singh Rathore, President-India Business, JB Pharma
Read More
